231 related articles for article (PubMed ID: 31246451)
1. Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.
Li X; Wu Y; Tian G; Jiang Y; Liu Z; Meng X; Bao X; Feng L; Sun H; Deng H; Li XD
J Am Chem Soc; 2019 Jul; 141(29):11497-11505. PubMed ID: 31246451
[TBL] [Abstract][Full Text] [Related]
2. An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains.
D'Ascenzio M; Pugh KM; Konietzny R; Berridge G; Tallant C; Hashem S; Monteiro O; Thomas JR; Schirle M; Knapp S; Marsden B; Fedorov O; Bountra C; Kessler BM; Brennan PE
Angew Chem Int Ed Engl; 2019 Jan; 58(4):1007-1012. PubMed ID: 30589164
[TBL] [Abstract][Full Text] [Related]
3. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
4. Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.
Clegg MA; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Leveridge M; Lindon M; Liwicki GM; Michon AM; Molnar J; Rioja I; Soden PE; Theodoulou NH; Werner T; Tomkinson NCO; Prinjha RK; Humphreys PG
J Med Chem; 2020 Jun; 63(11):5816-5840. PubMed ID: 32410449
[TBL] [Abstract][Full Text] [Related]
5. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
Fedorov O; Lingard H; Wells C; Monteiro OP; Picaud S; Keates T; Yapp C; Philpott M; Martin SJ; Felletar I; Marsden BD; Filippakopoulos P; Müller S; Knapp S; Brennan PE
J Med Chem; 2014 Jan; 57(2):462-76. PubMed ID: 24313754
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains.
Karim RM; Chan A; Zhu JY; Schönbrunn E
J Med Chem; 2020 Mar; 63(6):3227-3237. PubMed ID: 32091206
[TBL] [Abstract][Full Text] [Related]
7. Advancements in the Development of non-BET Bromodomain Chemical Probes.
Clegg MA; Tomkinson NCO; Prinjha RK; Humphreys PG
ChemMedChem; 2019 Feb; 14(4):362-385. PubMed ID: 30624862
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
Chen P; Chaikuad A; Bamborough P; Bantscheff M; Bountra C; Chung CW; Fedorov O; Grandi P; Jung D; Lesniak R; Lindon M; Müller S; Philpott M; Prinjha R; Rogers C; Selenski C; Tallant C; Werner T; Willson TM; Knapp S; Drewry DH
J Med Chem; 2016 Feb; 59(4):1410-24. PubMed ID: 25799074
[TBL] [Abstract][Full Text] [Related]
9. The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors.
Sasaki K; Yoshida M
Drug Discov Today Technol; 2016 Mar; 19():51-56. PubMed ID: 27769358
[TBL] [Abstract][Full Text] [Related]
10. Biological function and histone recognition of family IV bromodomain-containing proteins.
Lloyd JT; Glass KC
J Cell Physiol; 2018 Mar; 233(3):1877-1886. PubMed ID: 28500727
[TBL] [Abstract][Full Text] [Related]
11. Bromodomains: A novel target for the anticancer therapy.
Gokani S; Bhatt LK
Eur J Pharmacol; 2021 Nov; 911():174523. PubMed ID: 34563497
[TBL] [Abstract][Full Text] [Related]
12. Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors.
Karim RM; Bikowitz MJ; Chan A; Zhu JY; Grassie D; Becker A; Berndt N; Gunawan S; Lawrence NJ; Schönbrunn E
J Med Chem; 2021 Nov; 64(21):15772-15786. PubMed ID: 34710325
[TBL] [Abstract][Full Text] [Related]
13. Selective recognition of acetylated histones by bromodomains in transcriptional co-activators.
Hassan AH; Awad S; Al-Natour Z; Othman S; Mustafa F; Rizvi TA
Biochem J; 2007 Feb; 402(1):125-33. PubMed ID: 17049045
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain Histone Readers and Cancer.
Jain AK; Barton MC
J Mol Biol; 2017 Jun; 429(13):2003-2010. PubMed ID: 27890782
[TBL] [Abstract][Full Text] [Related]
15. Engineered bromodomains to explore the acetylproteome.
Bryson BD; Del Rosario AM; Gootenberg JS; Yaffe MB; White FM
Proteomics; 2015 May; 15(9):1470-5. PubMed ID: 25641834
[TBL] [Abstract][Full Text] [Related]
16. Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B.
Drouin L; McGrath S; Vidler LR; Chaikuad A; Monteiro O; Tallant C; Philpott M; Rogers C; Fedorov O; Liu M; Akhtar W; Hayes A; Raynaud F; Müller S; Knapp S; Hoelder S
J Med Chem; 2015 Mar; 58(5):2553-9. PubMed ID: 25719566
[TBL] [Abstract][Full Text] [Related]
17. Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching.
Philpott M; Rogers CM; Yapp C; Wells C; Lambert JP; Strain-Damerell C; Burgess-Brown NA; Gingras AC; Knapp S; Müller S
Epigenetics Chromatin; 2014; 7():14. PubMed ID: 25097667
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
[TBL] [Abstract][Full Text] [Related]
19. A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications.
Flynn EM; Huang OW; Poy F; Oppikofer M; Bellon SF; Tang Y; Cochran AG
Structure; 2015 Oct; 23(10):1801-1814. PubMed ID: 26365797
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain inhibitors and cancer therapy: From structures to applications.
Pérez-Salvia M; Esteller M
Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
